Supplements

coffee decreases liver disease risk

In plain terms: Is coffee good for your liver?

Strong support Supplements 🔬 Includes disconfirming

RefutedContestedStrong support

consensus score 0.79

This is one of coffee's strongest health links. Coffee drinkers have substantially lower rates of liver cancer, cirrhosis, and scarring (fibrosis) - often 40-50% lower at higher intakes. It seems to protect against liver-disease progression more than preventing fatty liver in the first place, but the signal is remarkably consistent.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

21 support 0 contradict 1 tested null 3 mixed · 25 sources, 19 independent groups

What the evidence shows

Coffee has an unusually strong and consistent link to better liver health: meta-analyses report substantially lower risk of liver cancer (HCC), cirrhosis, and advanced fibrosis in coffee drinkers, often 40–50% lower at higher intake, with a clear dose-response.

The evidence (25)

Source	Grade	Stance	Quality	Finding
Siani M et al 2026 · study_type: observational	observational	supports	low	Southern Italy cohort: MASLD odds decreased with increasing daily coffee, greatest benefit at 4-6 cups/day (OR 0.407, 95% CI 0.186-0.893) vs <1 cup/day.
Kennedy OJ et al. 2017 · BMJ Open	meta-analysis	supports	moderate	SR+meta 18 cohorts (2.27M): +2 cups/d gives 35% lower HCC (RR 0.65); GRADE very low (no RCTs).
Kositamongkol C et al. 2021 · Front Pharmacol	meta-analysis	mixed	moderate	Umbrella: no assoc with NAFLD incidence generally; reduced fibrosis in NAFLD patients (OR 0.67).
Zhou S et al 2025 · study_type: observational	observational	supports	moderate	Prospective cohort, 147,263 participants, 12.6yr median follow-up: unsweetened coffee showed dose-dependent lower risk of incident GI disease (HR 0.84 at 2-4 cups/day) with a significant additive interaction for cirrhosis specifically.
Goh GB et al. 2014 · Hepatology	observational	supports	high	Singapore Chinese (63k): >=2 cups/d nonviral cirrhosis mortality HR 0.34.
Liu F et al. 2015 · PLoS One	meta-analysis	supports	moderate	Meta 16 studies: cirrhosis OR 0.61, fibrosis OR 0.73, dose-dependent.
Liu W et al 2026 · study_type: observational	observational	supports	high	UK Biobank, 185,437 participants, median 10.5yr follow-up, 1536 MASLD cases: unsweetened/caffeinated coffee >2.5 servings/day gave HR 0.70 (0.60-0.82) and 0.78 (0.67-0.91) for MASLD; sugar/artificially-sweetened coffee showed no association
Park SY et al. 2018 · Cancer Epidemiol Biomarkers Prev	observational	supports	high	Multiethnic Cohort (167k): >=4 cups/d liver cancer HR 0.57, consistent across 5 ethnicities.
Kim HS et al 2026 · study_type: observational	observational	supports	high	UK Biobank, 354,957 participants, ≥13yr follow-up: ≥5 cups/day vs none gave HR 0.68 (0.58-0.79) cirrhosis, 0.53 (0.34-0.83) HCC, 0.58 (0.45-0.74) liver mortality; imaging showed lower hepatic fat/iron/fibroinflammation and favorable proteom
Vargas-Pozada EE et al 2025 · study_type: observational	observational	supports	moderate	Narrative/mechanistic review: cites epidemiological and clinical evidence that regular coffee consumption reduces risk of liver disease progression to fibrosis, cirrhosis, and HCC, alongside lower liver enzymes and reduced liver-disease mor
Di Maso M et al. 2021 · Adv Nutr	meta-analysis	mixed	moderate	Dose-response meta: HCC RR 0.93 (0.80-1.08), trending protective but not statistically significant.
Ebadi M et al. 2021 · Nutrients	meta-analysis	mixed	moderate	Meta: no assoc with NAFLD incidence (RR 0.88 ns) BUT 35% lower significant fibrosis (RR 0.65).
Emadi RC et al 2025 · study_type: observational	observational	supports	moderate	Broad narrative review of coffee and health: moderate coffee intake (3-5 cups/day) associated with reduced risk of several diseases including liver and uterine cancers, based on large prospective cohorts.
Yu C et al. 2016 · Sci Rep	meta-analysis	supports	high	Dose-response meta 20 cohorts: highest vs occasional liver cancer RR 0.55; linear dose-response.
Pham K et al 2025 · study_type: meta-analysis	meta-analysis	supports	high	Systematic review of 59 Mendelian randomisation studies (160 disease/biomarker associations): probable evidence for a protective effect of genetically-predicted coffee consumption on hepatocellular carcinoma risk.
Bravi F et al. 2017 · Eur J Cancer Prev	meta-analysis	supports	high	Meta: HCC RR 0.66 and chronic liver disease RR 0.62 in coffee drinkers.
Setiawan VW et al. 2015 · Gastroenterology	observational	supports	high	Multiethnic Cohort (162k): >=4 cups/d HCC RR 0.59; chronic-liver-disease mortality RR 0.29.
Geier A et al 2026 · study_type: observational	observational	supports	moderate	German SLD-Registry, 903 MASLD patients: high-risk liver stiffness (≥9.6kPa) less frequent among coffee consumers vs non-consumers (OR 0.58, 95% CI 0.34-0.97, p=0.04) with significant dose-dependency (p<0.003).
Whitfield JB et al. 2021 · J Hepatol	observational	tested-null	moderate	Coffee did NOT improve genetic/clinical risk-score prediction of alcohol-related cirrhosis (null).
Chen P et al 2026 · study_type: observational	observational	supports	low	NHANES 2013-2018, 8062 adults: coffee consumption inversely associated with NAFLD (OR 0.96, 95% CI 0.94-0.99) after adjustment; 2 cups/day optimal in women.
Bravi F et al. 2013 · Clin Gastroenterol Hepatol	meta-analysis	supports	high	Meta 16 studies: any coffee HCC RR 0.60; high intake RR 0.44.
Kwapien E et al 2025 · study_type: observational	observational	supports	low	Broad narrative review of coffee's systemic health effects: cites reduced risk of liver cancer and lower incidence of liver fibrosis among the metabolic/chemopreventive benefits of moderate coffee intake.
Khalifa R et al 2025 · study_type: observational	observational	supports	moderate	Narrative review of epidemiological/clinical evidence: regular coffee intake linked to reduced progression to fibrosis, cirrhosis, and HCC across chronic liver diseases, with optimal dose at 3-4 cups/day.
Bai K et al. 2016 · Onco Targets Ther	meta-analysis	supports	moderate	Meta 11 studies: HCC pooled OR 0.49.
Hayat U et al. 2020 · Ann Hepatol	meta-analysis	supports	moderate	Meta 11 studies: NAFLD RR 0.77; lower fibrosis risk.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.